Receptor Activator of Nuclear Factor κB Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis

Lignende værker

• Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
  af: Wasilewska, Anna, et al.
  Udgivet: (2010)
• RANKL/RANK/OPG: key therapeutic target in bone oncology
  af: Ando, Kosei, et al.
  Udgivet: (2008)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  af: Martin Widschwendter, et al.
  Udgivet: (2015-10-01)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  af: Widschwendter, Martin, et al.
  Udgivet: (2015)
• Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
  af: Picarda, Gaëlle, et al.
  Udgivet: (2013)